+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 2 Actively Recruiting clinical trials

C

Actively Recruiting

Researchers are evaluating radiation therapy options for men with high-risk prostate cancer in this phase III trial. The study compares a shorter course of stereotactic body radiation therapy SBRT, which delivers five high-dose treatments over two weeks, to the usual longer radiation therapy given over 4 to 9 weeks. The goal is to see if the shorter treatment is as effective in preventing cancer from returning as the standard therapy. Participants are randomly assigned to one of two groups the first group receives SBRT with five treatments over two weeks, and the second group undergoes external beam radiation therapy EBRT with 20 to 45 treatments over 4 to 9 weeks. Both groups may have bone scans, CT, MRI, or PETCT scans during screening and on study, and they may optionally provide blood and urine samples. This trial includes follow-up visits every six months for five years to monitor outcomes. During the study, participants will have various assessments including imaging and questionnaires to evaluate urinary, bowel, sexual function, fatigue, quality of life, and treatment burden. Researchers will track metastasis-free survival, failure-free survival, overall survival, adverse events, and patient-reported outcomes up to 15 years. The study aims to provide detailed information about the effectiveness and impact of the shorter radiation therapy compared to the usual treatment.

Age: 18Years +MALEPhase 3
436 locations
C

Actively Recruiting

Researchers are comparing two treatment methods for patients with high-grade T1 non-muscle invasive bladder cancer. This phase II trial evaluates pembrolizumab combined with radiation therapy against the usual chemotherapy regimens paired with radiation. Pembrolizumab, an immunotherapy drug, may help the immune system attack cancer cells, while chemotherapy drugs and radiation therapy work to kill or stop the growth of tumor cells. The goal is to see which combination better controls the cancer while preserving the bladder. Participants are randomly assigned to one of two groups. One group receives chemotherapy drugs chosen by their physiciancisplatin weekly for 4 weeks, gemcitabine on multiple days over several weeks, or mitomycin with continuous 5-fluorouracil infusionsalong with radiation therapy delivered in 20, 32, or 36 sessions over 4 to 7 weeks. The other group receives pembrolizumab infusions every 6 weeks for up to 9 cycles, also combined with the same radiation therapy schedule. Treatments continue as long as the disease does not progress and side effects remain acceptable. Throughout the study, participants undergo CT and MRI scans and provide blood samples, with optional urine samples. After completing treatment, participants are followed regularly for up to 10 years, with visits every 3 months for 2 years, every 6 months for 3 years, then annually for 5 years. Researchers monitor bladder intact event-free survival, quality of life, response by cystoscopy, disease-free and overall survival, local and metastatic cancer control, and side effects. Quality of life questionnaires and fatigue assessments are also completed to understand the broader impact of treatments.

Age: 18Years +All GendersPhase 2
147 locations